David Simpson is the founder of Iksuda Therapeutics. Latest round: Series B. Backed by North East Technology Fund. Based in Newcastle, United Kingdom.
David Simpson is the Co-founder and CEO of Iksuda Therapeutics, a biotech company focused on developing Antibody Drug Conjugates (ADCs) for solid tumors. He co-founded the company in 2012, initially named Glythera, and later refocused it on ADC development.
Full founder directory · Investor directory · Company funding database · Fundraising library